Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
58.00
-1.59 (-2.67%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Belite Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Belite Bio stock have an average target of 96.67, with a low estimate of 80 and a high estimate of 110. The average target predicts an increase of 66.67% from the current stock price of 58.00.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2025.
Analyst Ratings
The average analyst rating for Belite Bio stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +37.93% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +72.41% | Mar 18, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $57 → $79 | Strong Buy | Maintains | $57 → $79 | +36.21% | Jan 21, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $60 → $110 | Strong Buy | Maintains | $60 → $110 | +89.66% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
n/a
from 255.78M
Revenue Next Year
n/a
EPS This Year
-1.44
from -1.18
EPS Next Year
-1.46
from -1.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52.5M | 26.3M | 132.8M | ||
| Avg | 10.2M | 6.4M | 94.2M | ||
| Low | n/a | n/a | 56.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -79.5% | 157.4% | 1,983.6% | ||
| Avg | -96.0% | -37.5% | 1,377.1% | ||
| Low | - | - | 791.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.16 | -0.37 | 1.05 | ||
| Avg | -1.44 | -1.46 | -0.03 | ||
| Low | -1.71 | -2.03 | -0.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.